SEC Tracker
Get the app
HROW · XBRL financial data

Harrow financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (HROW's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023†Mar 31, 2024†Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers34,26536,355*34,58748,93949,25766,831*47,83163,74271,63889,092*44,20370,661
Cost of goods and services sold10,06711,302*10,55312,53912,01814,135*15,52416,23017,71218,468*17,15820,298
Gross profit24,19825,053*24,03436,40037,23952,696*32,30747,51253,92670,624*27,04550,363
Research and development1,4213,336*2,1493,0532,2734,755*3,0262,8683,32311,723*5,8958,072
Selling, general and administrative21,03326,212*28,81331,81733,64534,789*40,51333,23535,85643,310*43,23053,298
Total operating expenses22,45429,928*30,96234,87035,91839,797*43,53936,10339,17955,033*49,12561,370
Operating income (loss)1,744(4,875)*(6,928)1,5301,32112,899*(11,232)11,40914,74715,591*(22,080)(11,007)
Interest expense5,7495,124*5,4155,4715,5256,375*6,5486,4086,0385,186*5,4976,263
Other income (expense)(195)(100)*26464(261)*—(6)61(8)*—0
Income tax expense (benefit)1,539(535)*—65520(514)*—0—year only250
Net income (loss)(4,391)(9,148)*(13,565)(6,473)(4,220)6,777*(17,780)4,9951,0206,626*(27,602)(17,270)
Earnings per share, basic USD per share(0.13)(0.26)*(0.38)(0.18)(0.12)0.19*(0.50)0.140.030.18*(0.74)(0.46)
Earnings per share, diluted USD per share(0.13)(0.26)*(0.38)(0.18)(0.12)0.19*(0.50)0.130.030.20*(0.74)(0.46)
Weighted average shares, basic thousands of shares34,25535,389*35,47035,61935,70235,810*35,82636,79037,14537,260*37,23137,350
Weighted average shares, diluted thousands of shares34,25535,389*35,47035,61935,70235,810*35,82638,85438,87533,489*37,23137,350
  • † Share count changed about 1/999 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1003x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (HROW's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023†Mar 31, 2024†Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents65,61074,08568,53870,96872,60147,24766,72652,96374,29072,92794,64483,889
Short-term investments8,2658,6817,433—————————
Accounts receivable18,46836,26128,96051,98853,734116,37377,06378,82277,600110,895101,259118,559
Inventory8,92410,86710,8109,42510,15610,70210,71611,55212,83413,52316,49616,910
Prepaid and other current assets9,0119,5889,7177,00910,57115,32915,03011,55312,88014,40513,9859,949
Total current assets110,278139,482125,458139,390147,062189,651169,535154,890177,604211,750226,384229,307
Property and equipment, net3,6293,5213,3893,2883,6253,7343,5683,5123,3803,2603,1302,960
Right-of-use asset6,9726,7856,9686,7709,3798,5548,3378,1557,9717,7837,5917,394
Goodwill332332332332332332332332332332332332
Total assets286,065312,164295,536306,630351,539388,971364,164345,033363,074399,482419,543416,816
Accounts payable—————38,76237,09523,41518,99335,35526,12526,265
Accrued liabilities59———————————
Total current liabilities19,02949,34441,75353,55195,00591,343186,986248,88465,40096,30291,439102,171
Lease liability, non-current6,7356,5246,7166,5439,5008,7928,5818,3668,1397,9057,6667,421
Total liabilities210,663241,753235,330248,453293,918319,674308,068295,734316,413347,391391,192401,971
Accumulated deficit(124,756)(133,904)(147,469)(153,942)(158,162)(151,385)(169,165)(164,170)(163,150)(156,524)(184,126)(201,396)
Total stockholders' equity75,75770,76660,56158,53257,97669,65256,45149,65447,01652,44628,70615,200
Total liabilities and equity286,065312,164295,536306,630351,539388,971364,164345,033363,074399,482419,543416,816
Common shares outstanding (cover page) thousands of shares35,11835,3633535,48335,61535,65436,70037,00237,03737,23037,27537,488
  • † Share count changed about 1/999 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1003x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (HROW's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023†Mar 31, 2024†Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(4,391)(9,148)*(13,565)(6,473)(4,220)6,777*(17,780)4,9951,0206,626*(27,602)(17,270)
Stock-based compensation4,476*4,175*4,1694,271*4,385*4,794*4,556875*3,271*3,800*3,8373,788*
Net cash from operating activities(1,208)*8,696*(4,628)(2,746)*2,951*year only19,668(803)*16,588*8,411*(8,992)(9,755)*
Purchases of property and equipment520*194*92344*604*555*170166*210*341*194491*
Net cash from investing activities(20,131)*(203)*(110)5,103*(597)*(37,560)*(212)(293)*(225)*(4,730)*(18,203)(534)*
Proceeds from issuing common stock—year only——————————
Net cash from financing activities64,195*(18)*(809)73*(721)*29,985*23(12,667)*4,964*(5,044)*48,912(466)*
Net change in cash42,856*8,475*(5,547)2,430*1,633*(25,354)*19,479(13,763)*21,327*(1,363)*21,717(10,755)*
  • † Share count changed about 1/999 in the period ending 2024-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
  • † Share count changed about 1003x in the period ending 2024-06-30, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Harrow83,88970,661(9,755)*37.5M8.6 quarters 10-QJun 30, 2026
Aurinia Pharmaceuticals45,79283,69946,367*134.0M— 10-QSep 30, 2026
Novavax191,45856,698(72,807)*164.9M9.9 quarters 10-QJun 30, 2026
Neogen172,000222,80012,900218.3M— 10-QAug 31, 2026
Akebia Therapeutics155,54849,1283,525*277.1M— 10-QJun 30, 2026
Viridian Therapeutics164,986not reported(105,324)*113.3M9.3 quarters 10-QJun 30, 2026
Collegium Pharmaceutical129,467199,87871,323*32.6M— 10-QJun 30, 2026
Ardelyx46,317127,6552,171*251.4M— 10-QSep 30, 2026
Spyre Therapeutics82,727not reported(77,495)*95.0M15.7 quarters 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.